摘要
欧洲抗风湿病联盟(the European League Against Rheumatism,EULAR)于2008年2月发布第1版针对系统性红斑狼疮(systemic lupus erythematosus,SLE)的治疗推荐,被普遍认可并广泛应用于临床。在此基础上EULAR多次更新并完善了SLE疾病监测、并发症防治及妊娠管理等多方面内容。2019年3月,EULAR再次对SLE治疗推荐进行更新,本次重点更新了首要原则、生物制剂使用、个体化治疗方案及多靶点治疗策略,这为SLE规范化和个体化的"达标治疗"奠定了良好的基础。
The European League Against Rheumatism(EULAR) issued the first edition of the treatment recommendation for systemic lupus erythematosus in February 2008, which is widely recognized and used in clinical practice. On this basis, the recommendation was updated repeatedly by EULAR to improve the disease monitoring and prevention of complications, pregnancy management and many other aspects. In March 2019, EULAR updated the treatment recommendation for SLE, which focusing on updating the first principles, the use of biological agents, individualized treatment programs and multi-target treatment strategies. This laid a good foundation for standardization and individualization of SLE treatment.
作者
杨欣
李学义
YANG Xin;LI Xue-yi(Department of Rheumatology,the Second Affiliated Hospital ofXi'an Jiaotong University,Xi'an 710004,Shaanxi Province,China)
出处
《世界临床药物》
CAS
2019年第6期375-382,共8页
World Clinical Drug
关键词
欧洲抗风湿病联盟
系统性红斑狼疮
治疗推荐
the European League Against Rheumatism
systemic lupus erythematosus
treatment recommendation
